NCT02499952 - Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

January 13, 2017

Study Completion Date

January 13, 2017

Conditions

Germ Cell NeoplasmsTesticular NeoplasmsNon Seminomatous Germ Cell TumorsMediastinal NeoplasmsGenital Neoplasms, MaleGenital Neoplasms, FemaleOvarian Neoplasms

Interventions

DRUG

Pembrolizumab

200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.

Trial Locations (2)

19104

University of Pennsylvania, Philadelphia

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis